Arkolith/Insider Trading/BPMC/Form 4

Haviland Kate

Chief Executive Officer, DirectorBlueprint Medicines Corp (BPMC) · full profile →Form 4 · filed Jul 21, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
13
3 non-derivative · 10 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 17, 2025Grant(A)129K——295K
Jul 17, 2025Tender(U)71K——0
Jul 17, 2025Disposed to issuer(D)224K——71K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 17, 2025Disposed to issuer(D)2——0
Jul 17, 2025Disposed to issuer(D)591——0
Jul 17, 2025Disposed to issuer(D)39K——0
Jul 17, 2025Disposed to issuer(D)33K——0
Jul 17, 2025Disposed to issuer(D)70K——0
Jul 17, 2025Disposed to issuer(D)26K——0
Jul 17, 2025Disposed to issuer(D)80K——0
Jul 17, 2025Disposed to issuer(D)80K——0
Jul 17, 2025Disposed to issuer(D)80K——0
Jul 17, 2025Disposed to issuer(D)29K——0

Transaction Codes

A
Grant / award
U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-069386) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML